Overall, RASSF1A promoter methylation was detected in 46.7% (57/122) of the patients, a frequency that did not differ between smokers and never-smokers [48.1% (39/81) vs. 43.9% (18/41), p = 0.645], or between adenocarcinoma and the group of other tumor types [51.4% (37/72) vs. 40% (20/50), p = 0.210], or between stage-I and the group of other stages [51.9% (28/54) vs. 40.7% (22/54), p = 0.247]. The gene discussed is RASSF1; the disease is adenocarcinoma.